Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published March 1, 2008 | public
Journal Article Open

Lethal Mutagenesis of Picornaviruses with N-6-Modified Purine Nucleoside Analogues

Abstract

RNA viruses exhibit extraordinarily high mutation rates during genome replication. Nonnatural ribonucleosides that can increase the mutation rate of RNA viruses by acting as ambiguous substrates during replication have been explored as antiviral agents acting through lethal mutagenesis. We have synthesized novel N-6-substituted purine analogues with ambiguous incorporation characteristics due to tautomerization of the nucleobase. The most potent of these analogues reduced the titer of poliovirus (PV) and coxsackievirus (CVB3) over 1,000-fold during a single passage in HeLa cell culture, with an increase in transition mutation frequency up to 65-fold. Kinetic analysis of incorporation by the PV polymerase indicated that these analogues were templated ambiguously with increased efficiency compared to the known mutagenic nucleoside ribavirin. Notably, these nucleosides were not efficient substrates for cellular ribonucleotide reductase in vitro, suggesting that conversion to the deoxyriboucleoside may be hindered, potentially limiting genetic damage to the host cell. Furthermore, a high-fidelity PV variant (G64S) displayed resistance to the antiviral effect and mutagenic potential of these analogues. These purine nucleoside analogues represent promising lead compounds in the development of clinically useful antiviral therapies based on the strategy of lethal mutagenesis.

Additional Information

Copyright © 2008, American Society for Microbiology. Received 10 August 2007/ Returned for modification 1 October 2007/ Accepted 31 December 2007. Published ahead of print on 7 January 2008. Financial support was provided by the National Institutes of Health (AI054776 to C.E.C., B.R.P., and J.M.B.), the MRC Development Gap Fund (financial assistance to K.T.), and the American Heart Association (established investigator award 0340028N to C.E.C. and predoctoral fellowships to J.P.E. and D.A.H.). We thank Danny Yun and Jeff Baldwin for cloning and purifying RNR using the BL21(DE3)/pET22b expression system. We thank Nora Chapman and Steven Tracy (University of Nebraska Medical Center) for providing plasmids encoding CVB3 cDNA. Supplemental material for this article may be found at http://aac.asm.org/.

Files

GRAaac08Figure_S_1.pdf
Files (1.8 MB)
Name Size Download all
md5:6e8edacea006299be36b982fc133ef66
49.4 kB Preview Download
md5:44cbcc7d3d159dc70f903d21c7528467
845.4 kB Download
md5:e16da31750f368b89075c3da0bd2aef1
94.0 kB Preview Download
md5:dd5b2c8a614a992242b52ba6c142b6c4
789.5 kB Preview Download
md5:9d6723a2f9896911ab6a8e1b230292d9
52.7 kB Download

Additional details

Created:
August 22, 2023
Modified:
October 16, 2023